November 1, 2024- Abbott announced that its FreeStyle Libre 2 and 3 systems can now be worn during common imaging procedures, such as X-rays, CT scans and MRIs. The U.S. Food and Drug Administration (FDA) cleared the removal of the imaging contraindication, making Abbott’s systems the first and only patient-applied continuous glucose monitoring (CGM) sensors approved for these screenings.
Diabetes can cause complications like cardiovascular disease, neuropathy, and infections, according to Abbott. Imaging procedures are often part of diabetes care: X-rays detect bone injuries, CT scans identify kidney stones and blood clots, and MRIs provide detailed images of organs and tissues to identify issues such as brain injuries, ischemic heart disease and fatty liver disease.
People who use FreeStyle Libre 2 and 3 systems rely on their CGM sensors to make important decisions about their diabetes, including when to take insulin. They will no longer have to remove and discard their CGM sensor before its wear time has ended, providing them with increased convenience and the potential to save money.